BNP Paribas Financial Markets Raises Stake in ABIVAX Société Anonyme (NASDAQ:ABVX)

BNP Paribas Financial Markets increased its stake in ABIVAX Société Anonyme (NASDAQ:ABVX) by 82.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,044 shares of the company’s stock after purchasing an additional 5,900 shares during the quarter. BNP Paribas Financial Markets’ holdings in ABIVAX Société Anonyme were worth $150,000 at the end of the most recent quarter.

Separately, abrdn plc increased its holdings in ABIVAX Société Anonyme by 167.7% in the third quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after buying an additional 198,225 shares in the last quarter. Institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Stock Up 0.5 %

ABVX stock opened at $7.94 on Wednesday. The stock’s 50 day moving average price is $9.40 and its 200 day moving average price is $11.23. ABIVAX Société Anonyme has a 1 year low of $7.11 and a 1 year high of $17.02.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ABVX. JMP Securities initiated coverage on ABIVAX Société Anonyme in a research note on Wednesday, December 4th. They set an “outperform” rating and a $33.00 price target on the stock. Citizens Jmp upgraded ABIVAX Société Anonyme to a “strong-buy” rating in a research report on Wednesday, December 4th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, ABIVAX Société Anonyme currently has a consensus rating of “Buy” and a consensus target price of $38.67.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.